Post by icemandios on Mar 11, 2016 4:47:34 GMT
TransEnterix to Exhibit at Society of American Gastrointestinal and Endoscopic Surgeons Annual Meeting
Highlighting two robotic surgery platforms at major general surgery meeting
TransEnterix, Inc. (NYSE MKT: TRXC) today announced that it will exhibit at the 2016 Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Annual Meeting. The Company’s multi-port robotic platform, the ALF-X® System, will be exhibited alongside the Company’s single-port robotic platform, the SurgiBot™ System. SAGES will be held March 16-19, 2016 at the Hynes Convention Center in Boston, Massachusetts. This represents the first major medical meeting at which TransEnterix will display both of its robotic platforms.
“SAGES is an important gathering of the leaders of minimally invasive surgery, and we are pleased to display our two new robotic surgery platforms, which will continue to advance the field,” said Todd M. Pope, President and CEO of TransEnterix. “Robotics is forecasted to grow rapidly in the coming years and these two new technologies represent the first anticipated new entrants to help accelerate the adoption of robotic surgery globally.”
A demonstration and Q&A with Company management will be held for investors and attending media at 10am on Friday, March 18, 2016 at the TransEnterix booth (#1209).
About TransEnterix
TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the development and commercialization of the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform, and the ALF-X® System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye tracking camera control. The SurgiBot System is not available for sale in the U.S. The ALF-X has been granted a CE Mark, and is commercially available in Europe, but is not available for sale in the U.S. For more information, visit TransEnterix online at www.transenterix.com.
Highlighting two robotic surgery platforms at major general surgery meeting
TransEnterix, Inc. (NYSE MKT: TRXC) today announced that it will exhibit at the 2016 Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Annual Meeting. The Company’s multi-port robotic platform, the ALF-X® System, will be exhibited alongside the Company’s single-port robotic platform, the SurgiBot™ System. SAGES will be held March 16-19, 2016 at the Hynes Convention Center in Boston, Massachusetts. This represents the first major medical meeting at which TransEnterix will display both of its robotic platforms.
“SAGES is an important gathering of the leaders of minimally invasive surgery, and we are pleased to display our two new robotic surgery platforms, which will continue to advance the field,” said Todd M. Pope, President and CEO of TransEnterix. “Robotics is forecasted to grow rapidly in the coming years and these two new technologies represent the first anticipated new entrants to help accelerate the adoption of robotic surgery globally.”
A demonstration and Q&A with Company management will be held for investors and attending media at 10am on Friday, March 18, 2016 at the TransEnterix booth (#1209).
About TransEnterix
TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the development and commercialization of the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform, and the ALF-X® System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye tracking camera control. The SurgiBot System is not available for sale in the U.S. The ALF-X has been granted a CE Mark, and is commercially available in Europe, but is not available for sale in the U.S. For more information, visit TransEnterix online at www.transenterix.com.